Skip to content
Review Open access

CRISPR-enabled biosensing of cancer-associated DNA methylation in cell-free DNA: molecular architectures, molecular sampling constraints, and translational biosensor engineering

Oct 2026 · Frontiers in Bioengineering and Biotechnology · Vol 14 · 0 citations · 128 references
Medicine

TL;DR

No native-state Cas methylation assay identified in this review has established clinically usable diagnostic performance, and reported analytical limits of detection and methylation-fraction discrimination cannot be extrapolated to clinical sensitivity without accounting for input, recovery, fragmentation, background, and decision thresholds.

Abstract

DNA methylation in circulating cell-free DNA (cfDNA) provides cancer-associated and tissue-of-origin information complementary to mutation-based liquid biopsy. Clustered regularly interspaced short palindromic repeats (CRISPR)-based sensing is challenging because 5-methylcytosine (5 mC) generally preserves Watson-Crick base pairing and is not inherently resolved by sequence-programmed CRISPR-associated (Cas) proteins. This targeted narrative review examines how methylated and unmethylated molecules are distinguished and converted into Cas-readable outputs under fragmented, low-input cfDNA conditions. We organize the literature into four discrimination routes comprising sequence conversion, enzymatic gating, affinity-assisted recognition, and native-state Cas modulation. Engineered molecular transduction is considered separately as a downstream enabling layer. We compare readouts in terms of quantitative fidelity and integration requirements. Sequence-conversion and enzymatic-gating systems have the broadest analytical evidence among the identified studies, largely from in vitro experiments. Direct affinity-assisted 5 mC-to-Cas sensing remains sparsely studied, and evidence for native-state sensing in patient-derived cfDNA is limited to exploratory observational comparisons. No native-state Cas methylation assay identified in this review has established clinically usable diagnostic performance. Reported analytical limits of detection and methylation-fraction discrimination cannot be extrapolated to clinical sensitivity without accounting for input, recovery, fragmentation, background, and decision thresholds. Translation requires validated biomarkers, fragment-matched calibration, orthogonal reference testing, reproducible device integration, and independent evaluation of locked assays in intended-use populations.

Read PDF

Similar papers

Oct 2026

Ligation-assisted DNA strand displacements and CRISPR/Cas14 cleavage for ultrasensitive detection of PIWI-interacting RNA.

PIWI-interacting RNA (piRNA) as a type of small non-coding RNA holds great promise for managing disease occurrence and progression. Herein, we construct a ligation-assisted DNA strand displacement strategy for enhanced CRISPR/Cas14 cleavage, which provides remarkable SERS and electrochemical responses to indicate trace...

Xiao-Qiang Li, Zhen-Zhen Guo, Wei-Feng Ye et al. · 0 citations
Open access Oct 2026

High-throughput droplet-based enzymatic DNA methylome profiling enables single-cell resolution of epigenetic heterogeneity

DNA methylation is a fundamental epigenetic modification that regulates gene expression, cellular identity, and disease-associated regulatory programs. However, high-throughput single-cell DNA methylation technologies have been limited by DNA degradation, low CpG recovery, and the poor scalability of bisulfite-based me...

Gao-Jie Li, Yang Yang, Zhuo-Ran Li et al. · 0 citations
Sep 2026

Modulating nanoconfined space charge for PCR-free and bisulfite-free detection of cfDNA methylation in ovarian cancer.

A bisulfite-free and PCR-free electrochemical nanochannel biosensor that modulates nanoconfined space charge to directly translate discrete epigenetic marks into measurable ion flux is reported, demonstrating great translational potential for precise epigenetic liquid biopsy.

Kai Hu, Zi-Meng Zhang, Bing-Heng Li et al. · 0 citations
Open access Oct 2026

A background-suppressed CRISPR/Cas13a-HRCA biosensor for ultrasensitive miR-137 detection toward differential screening of Alzheimer's disease.

Alzheimer's disease (AD) is associated with pathological changes that can occur years before the onset of clinical symptoms, highlighting the importance of sensitive biomarker detection for early diagnosis. Here, we developed a fluorescence biosensing platform based on CRISPR/Cas13a-assisted hyperbranched rolling circl...

Juan Song, Hui-Xin Yue, Chuan-Song Zhang et al. · 0 citations
Review Open access Oct 2026

Beyond DNA—CRISPR technologies for epigenome editing and transcriptional regulation in disease: A scoping review

Adoption of CRISPR epigenome editing is approaching clinical translation, but adoption will depend on rigorous causal target validation, standardized reporting, multilayer specificity assays, controllable delivery and evidence that corrected expression remains within a safe physiological window.

E. K. Oladipo, Victoria Oluwayemisi Adubiaran, A. Iyiola et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.